PL365292A1 - Zastosowanie długiej pentraksyny PTX3 do leczeniaschorzeń spowodowanych zmienioną aktywacją czynnika wzrostu FGF-2 - Google Patents

Zastosowanie długiej pentraksyny PTX3 do leczeniaschorzeń spowodowanych zmienioną aktywacją czynnika wzrostu FGF-2

Info

Publication number: PL365292A1
Authority: PL; Poland
Prior art keywords: growth factor; treatment; factor fgf; diseases caused; long pentraxin
Prior art date: 2000-11-08

Application number

PL01365292A

Other languages

English (en)

Other versions

PL205925B1 (pl

Inventor

Alberto Mantovani

Barbara Bottazzi

Marco Presta

Marco Rusnati

Original Assignee

Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-08

Filing date

2001-11-08

Publication date

2004-12-27

2001-11-08 Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.

2004-12-27 Publication of PL365292A1 publication Critical patent/PL365292A1/pl

2010-06-30 Publication of PL205925B1 publication Critical patent/PL205925B1/pl

Links

239000003102 growth factor Substances 0.000 title abstract 3
230000004913 activation Effects 0.000 title abstract 2
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
101150019331 FGF2 gene Proteins 0.000 title 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 2
101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 abstract 2
BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 abstract 2
102100027351 Pentraxin-related protein PTX3 Human genes 0.000 abstract 2
230000004071 biological effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Marine Sciences & Fisheries (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

PL365292A 2000-11-08 2001-11-08 Zastosowanie długiej pentraksyny PTX3 lub cDNA kodującego długą pentraksynę PTX3 PL205925B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT2000RM000578A IT1317930B1 (it)	2000-11-08	2000-11-08	Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PCT/IT2001/000563 WO2002038169A1 (en)	2000-11-08	2001-11-08	Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Publications (2)

Publication Number	Publication Date
PL365292A1 true PL365292A1 (pl)	2004-12-27
PL205925B1 PL205925B1 (pl)	2010-06-30

Family

ID=11454983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL365292A PL205925B1 (pl)	2000-11-08	2001-11-08	Zastosowanie długiej pentraksyny PTX3 lub cDNA kodującego długą pentraksynę PTX3

Country Status (21)

Country	Link
US (1)	US7858577B2 (pl)
EP (1)	EP1331940B1 (pl)
JP (1)	JP4167061B2 (pl)
KR (1)	KR100822357B1 (pl)
CN (1)	CN1304047C (pl)
AT (1)	ATE322906T1 (pl)
AU (2)	AU2251302A (pl)
BR (1)	BR0115190A (pl)
CA (1)	CA2428176C (pl)
CY (1)	CY1106092T1 (pl)
CZ (1)	CZ299673B6 (pl)
DE (1)	DE60118769T2 (pl)
DK (1)	DK1331940T3 (pl)
ES (1)	ES2261515T3 (pl)
HU (1)	HU229100B1 (pl)
IT (1)	IT1317930B1 (pl)
MX (1)	MXPA03004005A (pl)
PL (1)	PL205925B1 (pl)
PT (1)	PT1331940E (pl)
SK (1)	SK287791B6 (pl)
WO (1)	WO2002038169A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1298487B1 (it) *	1997-12-19	2000-01-10	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) *	2002-02-28	2003-08-28	Sigma Tau Ind Farmaceuti	Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
ITRM20020191A1 (it) *	2002-04-08	2003-10-08	Sigma Tau Ind Farmaceuti	Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
ITRM20030596A1 (it) *	2003-12-23	2005-06-24	Sigma Tau Ind Farmaceuti	Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
WO2005080981A1 (ja) *	2004-02-25	2005-09-01	Perseus Proteomics Inc.	血管障害の程度の判定方法
ITRM20040489A1 (it)	2004-10-08	2005-01-08	Sigma Tau Ind Farmaceuti	Pentraxina lunga ptx3 deglicosilata o desialidata.
US8076300B2 (en) *	2006-01-24	2011-12-13	Tecnogen S.P.A.	FGF2-binding peptides and uses thereof
EP1832295A1 (en) *	2006-03-10	2007-09-12	Tecnogen S.P.A.	Use of PTX3 for the treatment of viral diseases
RS52377B (sr)	2006-05-02	2012-12-31	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Primena timozina 1, samog ili u kombinaciji sa ptx3 ili ganciklovirom, za lečenje infekcije citomegalovirusom
WO2013191280A1 (ja) *	2012-06-22	2013-12-27	国立大学法人東京大学	全身性炎症反応症候群の治療又は予防剤
US12613349B2 (en)	2023-01-17	2026-04-28	GE Precision Healthcare LLC	Flat panel X-ray detector for computed tomography

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0571442A4 (en) *	1991-01-14	1995-05-03	Univ New York	PROTEIN TSG-14 INDUCED BY CYTOKINE, DNA ENCODING THE PROTEIN AND USES THEREOF.
IT1298487B1 (it) *	1997-12-19	2000-01-10	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,

2000
- 2000-11-08 IT IT2000RM000578A patent/IT1317930B1/it active
2001
- 2001-11-08 PL PL365292A patent/PL205925B1/pl unknown
- 2001-11-08 AU AU2251302A patent/AU2251302A/xx active Pending
- 2001-11-08 DE DE60118769T patent/DE60118769T2/de not_active Expired - Lifetime
- 2001-11-08 KR KR1020037006278A patent/KR100822357B1/ko not_active Expired - Fee Related
- 2001-11-08 AT AT01993471T patent/ATE322906T1/de active
- 2001-11-08 US US10/416,225 patent/US7858577B2/en not_active Expired - Fee Related
- 2001-11-08 DK DK01993471T patent/DK1331940T3/da active
- 2001-11-08 JP JP2002540751A patent/JP4167061B2/ja not_active Expired - Fee Related
- 2001-11-08 AU AU2002222513A patent/AU2002222513B8/en not_active Ceased
- 2001-11-08 WO PCT/IT2001/000563 patent/WO2002038169A1/en not_active Ceased
- 2001-11-08 EP EP01993471A patent/EP1331940B1/en not_active Expired - Lifetime
- 2001-11-08 PT PT01993471T patent/PT1331940E/pt unknown
- 2001-11-08 ES ES01993471T patent/ES2261515T3/es not_active Expired - Lifetime
- 2001-11-08 BR BR0115190-8A patent/BR0115190A/pt active Search and Examination
- 2001-11-08 MX MXPA03004005A patent/MXPA03004005A/es active IP Right Grant
- 2001-11-08 CZ CZ20031179A patent/CZ299673B6/cs not_active IP Right Cessation
- 2001-11-08 HU HU0400541A patent/HU229100B1/hu not_active IP Right Cessation
- 2001-11-08 SK SK562-2003A patent/SK287791B6/sk not_active IP Right Cessation
- 2001-11-08 CA CA2428176A patent/CA2428176C/en not_active Expired - Fee Related
- 2001-11-08 CN CNB018185630A patent/CN1304047C/zh not_active Expired - Fee Related
2006
- 2006-06-05 CY CY20061100719T patent/CY1106092T1/el unknown

Also Published As

Publication number	Publication date
ITRM20000578A1 (it)	2002-05-08
ES2261515T3 (es)	2006-11-16
CY1106092T1 (el)	2011-06-08
DE60118769T2 (de)	2007-01-04
PT1331940E (pt)	2006-07-31
CN1473050A (zh)	2004-02-04
SK287791B6 (sk)	2011-10-04
SK5622003A3 (en)	2003-10-07
US7858577B2 (en)	2010-12-28
CA2428176A1 (en)	2002-05-16
EP1331940A1 (en)	2003-08-06
CZ20031179A3 (cs)	2003-11-12
BR0115190A (pt)	2004-02-03
MXPA03004005A (es)	2004-05-05
WO2002038169A1 (en)	2002-05-16
EP1331940B1 (en)	2006-04-12
AU2251302A (en)	2002-05-21
DK1331940T3 (da)	2006-08-14
HUP0400541A3 (en)	2006-01-30
US20040023879A1 (en)	2004-02-05
DE60118769D1 (de)	2006-05-24
CZ299673B6 (cs)	2008-10-15
KR100822357B1 (ko)	2008-04-16
HUP0400541A2 (hu)	2004-05-28
HU229100B1 (en)	2013-07-29
IT1317930B1 (it)	2003-07-15
CN1304047C (zh)	2007-03-14
JP4167061B2 (ja)	2008-10-15
AU2002222513B2 (en)	2006-10-26
CA2428176C (en)	2013-02-05
JP2004513151A (ja)	2004-04-30
HK1061209A1 (en)	2004-09-10
PL205925B1 (pl)	2010-06-30
KR20030061396A (ko)	2003-07-18
ATE322906T1 (de)	2006-04-15
AU2002222513B8 (en)	2006-11-23

Publication	Publication Date	Title
DE60023043D1 (de)	2006-02-16	(S,S)-Reboxetin zur Behandlung von Inkontinenz
NZ504026A (en)	2002-12-20	Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
KR920019342A (ko)	1992-11-19	골질환 치료제
DE69116380D1 (de)	1996-02-22	Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
HK1045816A1 (zh)	2002-12-13	角质细胞生长因子-2制剂
AU2251302A (en)	2002-05-21	Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
BRPI0414215A (pt)	2006-11-07	tienopirazóis
SE0102147D0 (sv)	2001-06-18	New methods
ZA991749B (en)	1999-09-16	Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy.
DE60113304D1 (de)	2005-10-13	Verwendung von langem pentraxin ptx3 zur herstellung eines arzneimittels zur verhütung und heilung von autoimmunkrankheiten
AU3401093A (en)	1993-09-09	Therapeutic agent for threatened abortion
ZA982068B (en)	1998-09-16	Agent for preventing and/or treating cachexia
MXPA03011186A (es)	2004-02-26	Uso de pentraxina ptx3 de cadena larga para tratamiento contra enfermedades tumorales mediadas por fgf-8.
AP2009004857A0 (en)	2009-06-30	Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
PT869785E (pt)	2002-12-31	4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
DE3769497D1 (de)	1991-05-29	Mittel zur bekaempfung von phytopathogenen mikroben.
NO953003L (no)	1996-01-30	Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
DE59805246D1 (de)	2002-09-26	Tissue-faktor zur beeinflussung von gefässbildung
NZ514691A (en)	2004-02-27	Method to type prion proteins
ATE337783T1 (de)	2006-09-15	Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
BR0303384A (pt)	2004-03-30	Citalopram e seus usos no tratamento de pressão sanguìnea elevada
SI1331940T1 (sl)	2006-08-31	Uporaba dolgega pentraksina PTX3 za zdravljenje bolezni, ki jih povzroca spremenjena aktivnost rastnih faktorjev FGF-2
SE9902674D0 (sv)	1999-07-12	New composition
UA32315A (uk)	2000-12-15	Спосіб накладання шкірного шва
FR2790641B1 (fr)	2005-02-25	Liquide de conservation de tissu humain ou animal, notamment de veines